MK-3795

PT2385 · Peloton Therapeutics, a subsidiary of Merck & Co.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-3795, covering 2024-09-24 to 2024-09-24. Get the full timeline:

Most recent: Clinical Trial Update: MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) [Phase 2]

See pricing